Marina Konopleva

Specific F1 ATP synthase inhibition delivers transient mitochondrial stress for selective targeting of acute myeloid leukemia

This study shows that inhibiting F1 ATP synthase with EB2023 causes transient mitochondrial stress in AML cells, enabling effective treatment without harming healthy tissues.

Menin maintains enhancer-promoter interactions in a leukemia-specific manner

The paper investigates Menin's role in enhancer-promoter interactions in MLL-rearranged and NPM1c leukemia models, finding context-dependent effects on transcriptional regulation and enhancer function.

A STAT3 Degrader Demonstrates Pre-clinical Efficacy in Venetoclax resistant Acute Myeloid Leukemia

This paper shows that targeting STAT3 with a degrader can overcome Venetoclax resistance in AML by reducing MCL1 and improving mitochondrial function.

Romaciclib, a CDK8/CDK19 inhibitor, can overcome venetoclax resistance through a combinatorial strategy

This study shows that romaciclib combined with venetoclax overcomes venetoclax resistance in AML through synergistic apoptosis induction and suppression of resistance pathways.

Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy

This study shows that resistant clones are rapidly selected in hematopoietic cell compartments with leukemic stem cell potential before relapse in patients treated with ivosidenib combination therapy.

Pitavastatin counteracts venetoclax resistance mechanisms in acute myeloid leukemia by depleting geranylgeranyl pyrophosphate

This study shows pitavastatin overcomes venetoclax resistance in AML by depleting GGPP, inducing apoptosis through PUMA upregulation and MCL-1 reduction, and suppressing mitochondrial metabolism.

Quiescent OXPHOS-high triple-negative breast cancer cells that persist after chemotherapy depend on BCL-XL for survival

This study identifies OXPHOS-high quiescent triple-negative breast cancer cells that survive chemotherapy and depend on BCL-XL for survival, showing that targeting BCL-XL enhances chemotherapy efficacy.

The ASNS inhibitor ASX-173 potentiates L-asparaginase anticancer activity

The paper identifies ASX-173 as a potent ASNS inhibitor that enhances the anti-cancer effects of L-asparaginase in leukemia and shows its potential across multiple cancer types.